Indivior PLC is a specialty pharmaceutical company with a leading position in the treatment of opioid use disorder and related behavioral health conditions. The company leverages a diverse portfolio of proprietary therapies and invests in innovative pipeline assets targeting substance use and mental health disorders.The company generates revenue primarily through the sale of branded pharmaceutical products, with a focus on long-acting injectable therapies and sublingual formulations targeting opioid use dis ...

The S&P SmallCap 600 Index is a stock market index established by Standard & Poor's that is designed to measure the performance of the small-cap segment of the market and is composed of 600 constituent companies in the U.S. equities market with market capitalizations between $1.2 billion and $8.0 billion. The index is designed to track companies that meet specific inclusion criteria to ensure that they are liquid and financially viable. For more information on the S&P SmallCap 600 and S&P Dow Jones Indices, ...

Core Insights - Indivior PLC has resolved its legacy U.S. Department of Justice matter by paying a total of $295 million, which eliminates a significant liability and simplifies its capital structure [1][2]. Group 1: Financial Resolution - The payment of $295 million was made using Indivior's cash on hand, leading to the termination of the resolution agreement with the DOJ [1]. - The CEO of Indivior expressed satisfaction with reaching this milestone, emphasizing the company's commitment to integrity and compliance [2]. Group 2: Company Mission and Vision - Indivior focuses on developing medicines for opioid use disorder (OUD) and aims to transform OUD into a recognized chronic disease with evidence-based treatment accessible to all patients [2]. - The company has a pipeline of product candidates designed to expand its offerings in the OUD treatment category [2].